News

Artery.com's "2018 Future Healthcare 100" list was officially released, and CGeneTech was honored to be listed

  • Categories:Media
  • Author:Arterial network
  • Origin:Arterial network
  • Time of issue:2018-12-20
  • Views:0

(Summary description)On December 18-19, 2018, Artery.com's "2018 Future Healthcare 100" Forum was held at Renaissance Beijing Hotel. More than 2,500 domestic and international healthcare industry elites attended the event.

Artery.com's "2018 Future Healthcare 100" list was officially released, and CGeneTech was honored to be listed

(Summary description)On December 18-19, 2018, Artery.com's "2018 Future Healthcare 100" Forum was held at Renaissance Beijing Hotel. More than 2,500 domestic and international healthcare industry elites attended the event.

  • Categories:Media
  • Author:Arterial network
  • Origin:Arterial network
  • Time of issue:2018-12-20
  • Views:0

  On December 18-19, 2018, Artery.com's "2018 Future Healthcare 100" Forum was held at Renaissance Beijing Hotel. More than 2,500 domestic and international healthcare industry elites attended the event.

 

   On the 18th, Artery.com released the four main lists of "2018 Future Healthcare 100": "China Healthcare Top 100", "China Medicine Top 100", "China Health Top 30" and "Overseas Top 100". The four main lists were "China Health List Top 30" and "Overseas List Top 100". Centurion is fortunate to occupy one of the top 100 China Medical List.


  In addition, Artery.com has added sub-lists (TOP5) in niche areas (rehabilitation robotics, DTP pharmacy, third-party medical services and 12 other areas), as well as "China Top Industrial Park TOP10" and "China Top Industrial New City TOP10" from 2018. ".


  In this era of exploring the future of healthcare, we are looking forward to new technological breakthroughs and innovations, model explorations and improvements that will bring more excitement to the future of human health.


  As an observer and recorder of the industry, we hope to see social change, economic ups and downs and consumer evolution from a Chinese and global perspective, and to discover the direction of change in the health care industry from a broader perspective. "The Future Healthcare 100 aims to select innovative Chinese healthcare companies that truly represent the future of healthcare, discover the core strengths of China's future healthcare industry, and promote the process of innovation and change in the healthcare industry.


  In 2018, the "Future Healthcare 100" list has gone through three stages of production: preliminary selection, review and validation, to explore the most promising companies in various healthcare segments. The list provides a benchmark for innovative companies, a guide for investment institutions and value for audiences.


  The list of companies on the Future Healthcare 100 China 2018 is as follows.

The list of companies on the Future of Healthcare 100 China Medicine list for 2018 is as follows.

 

The list of companies on the Future of Health 100 China Health List 2018 is as follows.

The list of overseas companies in the Future of Healthcare 100 2018 is as follows.

   The 2018 Future Healthcare Industry Report released by Arteries.com - Eggshell Research Institute points out that 2018 was a year of change in the healthcare sector, and China has made a series of achievements in the reform of the sector. The capacity of medical services has been strengthened, the capacity of public health services has been improved, the management of medical institutions has been gradually standardised, the coverage of medical insurance services has been further expanded, the support of regulators for innovative drugs has been stepped up, and medical-related innovative technologies have emerged ......
  These factors have led to the emergence of a number of high-profile companies in various healthcare innovation segments, from traditional companies with a strong commitment to innovation to start-ups that are making the most noise in the healthcare innovation process.
  The "Future Healthcare 100" 2018 annual awards are voted by a panel of judges selected from industry experts, investors and policy researchers, and selected by the Artery Network Content Center, the Eggshell Institute and industry judges, to present the "Future Healthcare 100 The final results include the "Future Healthcare 100" sub-list, the "City New Town" list and the "Park" list.
  The sub-lists include "Rehabilitation Robot", "DTP Pharmacy", "Third Party Medical Services", "Internet of Medical Things", "Pediatric Clinics ", "Paediatric Clinics", "Doctor Groups", "Digital Chinese Medicine", "Digital Equipment for Pharmacies ", "Insurance Payments", "Consumer Genetics", "Gene Editing", "Microbiology " twelve sub-lists, listed below.

2018 Future Healthcare 100 - China List The Industrial Park List/Industrial New City List is as follows.

Source: arterial.com

The

The listing application of Shengshi Tyco's new hypoglycemic drug Shenggliptin was accepted

Today, Shengshi Tyco has accepted the marketing application (NDA) of Shenggliptin, a DPP-4 inhibitor, submitted to the National Drug Administration (NMPA) for the treatment of type 2 diabetes.
2023-02-02
Quantity

"Quantity" Half Achieves Double Prosperity: Tyco's Class 1 New Hypoglycemic Drug Shenggliptin Uncovers Blindness Data

Today, Shengshi Tyco has completed a key clinical study on a class 1 new hypoglycemic drug under development: phase III clinical trial of DPP-4 inhibitor shenggliptin in the treatment of type 2 diabetes. A dose of 50mg can reach the preset end point of the trial. A therapeutic dose of "half the dose" will further improve the safety of this drug and is expected to become the best hypoglycemic drug in the same class.
2022-10-17

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO